[ORGANIZATION]
NCCN
Featured in 2 tracked stories · first seen
Situations
FDA and EMA progress for Rasonque pancreatic cancer drug
47 clusters · 326 sources · last updated
Latest: Greece provides new pancreatic cancer drug to patients
On 26 August 2026, the U.S. Food and Drug Administration (FDA) granted expedited approval to daraxonrasib, marketed as Rasonque, for treating adults with metastatic pancreatic ductal adenocarcinoma (PDAC). Developed by R
Cancer immunotherapy side effect research
2 clusters · 4 sources · last updated
Latest: Immunotherapy advancements and side effect management in cancer treatment
Research into cancer immunotherapy, specifically immune checkpoint inhibitors, highlights both the efficacy of these treatments and the significant challenges posed by immune-related adverse events (irAEs). These treatme